Key result
99mTc-annexin V uptake is ~42% higher in the RV versus LV in ARVC/D.
Why the study?
Apoptosis in ARVC/D is proposed as a key process mediating myocardial loss and ventricular dysfunction, but noninvasive assessment methods are lacking.
Does (99m)Tc-annexin V scintigraphy allow noninvasive assessment of regional myocardial apoptosis in patients with ARVC/D?
Observational (n=6)
Single-blind
No
Does (99m)Tc-annexin V scintigraphy allow noninvasive assessment of regional myocardial apoptosis in patients with ARVC/D?
Absolute Event Rate: 1.328% vs 0.936%
p-value: p=0.049
Noninvasive assessment of cardiac apoptosis using (99m)Tc-annexin V scintigraphy is feasible in ARVC/D and demonstrates a chamber-specific apoptotic process in a subset of patients.
May support noninvasive apoptosis assessment in ARVC/D; leaves open its diagnostic or monitoring role pending larger studies.
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a myocardial disease that predominantly affects the right ventricle (RV). Its hallmark feature is fibrofatty replacement of the RV myocardium. Apoptosis in ARVC/D has been proposed as an important process that mediates the slow, ongoing loss of heart muscle cells which is followed by ventricular dysfunction. We aimed to establish whether cardiac apoptosis can be assessed noninvasively in patients with ARVC/D. METHODS: Six patients fulfilling the ARVC/D criteria were studied. Regional myocardial apoptosis was assessed with (99m)Tc-annexin V scintigraphy. RESULTS: Overall, the RV wall showed a higher (99m)Tc-annexin V signal than the left ventricular wall (p = 0.049) and the interventricular septum (p = 0.026). However, significantly increased uptake of (99m)Tc-annexin V in the RV was present in only three of the six ARVC/D patients (p = 0.001, compared to (99m)Tc-annexin V uptake in the RV wall of the other three patients). CONCLUSION: Our results are suggestive of a chamber-specific apoptotic process. Although the role of apoptosis in ARVC/D is unsolved, the ability to assess apoptosis noninvasively may aid in the diagnostic course. In addition, the ability to detect apoptosis in vivo with (99m)Tc-annexin V scintigraphy might allow individual monitoring of disease progression and response to diverse treatments aimed at counteracting ARVC/D progression.
No takes yet. Share an insight, caveat, or question.
Campian et al. (2011) conducted an observational in Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) (n=6). 99mTc-annexin V scintigraphy vs. Left ventricular wall was evaluated on 99mTc-annexin V uptake ratio (p=0.049). 99mTc-annexin V scintigraphy demonstrated significantly higher uptake in the right ventricular wall compared to the left ventricular wall (p=0.049) in patients with ARVC/D, indicating chamber-specific apoptosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: